Drugs for Gastrointestinal Diseases Practice Questions

Q: Colonoscopy performed on a 25 year old woman with eating disorder showed dark brown to black pigmentary deposit in the lining of the large intestine. Histopathology of biopsy revealed pigment laden macrophages within the lamina propria. On probing, the woman revealed use of laxatives for 9 months to lose weight. What could be the probable laxative agent that could have caused these findings?

Senna. ***Senna*** - Chronic use of **anthraquinone laxatives** like senna [1] leads to **melanosis coli**, characterized by dark brown pigment in the colon. - Histopathology reveals **pigment-laden macrophages** in the lamina propria, confirming melanosis coli. *Castor oil* - **Castor oil** is a stimulant laxative that acts on the small intestine but does not typically cause **melanosis coli**. - Its primary action is to increase fluid secretion and bowel motility, rather than pigment deposition. *Bisacodyl* - **Bisacodyl** is a stimulant laxative that works locally in the colon to increase fluid and electrolyte secretion and stimulate peristalsis. - It works on different pharmacological mechanisms and typically does not cause the characteristic **pigment-laden macrophages** that define melanosis coli. *Sorbitol* - **Sorbitol** is an osmotic laxative that works by drawing water into the colon, softening stools and promoting bowel movements. - It does not induce the characteristic **darkening of the colonic mucosa** or the specific histological changes observed in melanosis coli.

Q: Mechanism of action of teduglutide in short bowel syndrome:

GLP-2 analog that inhibits apoptosis. ***GLP-2 analog that inhibits apoptosis*** - **Teduglutide** is a synthetic analog of **glucagon-like peptide-2 (GLP-2)**, which is a naturally occurring human hormone [1]. - Its primary mechanism in **short bowel syndrome** involves promoting mucosal growth and inhibiting epithelial cell apoptosis, thereby enhancing nutrient absorption and gut adaptation. *GLP-1 analogs that inhibits apoptosis* - **GLP-1 analogs** like exenatide or liraglutide are primarily used for **type 2 diabetes mellitus** to stimulate insulin secretion and suppress glucagon [2]. - While they can have some effects on gut motility, their main role is not in promoting mucosal growth or inhibiting apoptosis in the context of short bowel syndrome. *HT1A inhibitor* - **HT1A inhibitors** (5-HT1A receptor antagonists) are typically involved in modulating serotonin pathways, often with applications in conditions like **anxiety** or **depression**. - There is no known direct link between HT1A inhibition and the treatment of short bowel syndrome. *C-peptide analogs* - **C-peptide** is a byproduct of insulin production and has been studied for potential roles in preventing diabetes complications, particularly in relation to **microvascular complications** [3], [4]. - It does not play a direct role as a therapeutic agent for promoting intestinal adaptation or inhibiting apoptosis in short bowel syndrome.

Q: Which GI drug acts by irreversibly inhibiting H+/K+ ATPase?

Omeprazole. ***Omeprazole*** - **Omeprazole** is a **proton pump inhibitor (PPI)** that actively and **irreversibly inhibits** the **H+/K+ ATPase enzyme** (proton pump) in gastric parietal cells [1], [3] - This inhibition blocks the final step in acid secretion, leading to a profound and long-lasting reduction in **gastric acid production** [2], [3] - The irreversible binding means new pumps must be synthesized for acid secretion to resume [2] *Ranitidine* - **Ranitidine** is an **H2 receptor antagonist** that works by reversibly blocking histamine H2 receptors on parietal cells, reducing acid secretion [2] - It does **not directly inhibit the H+/K+ ATPase** enzyme *Sucralfate* - **Sucralfate** is a **mucosal protectant** that forms a viscous, paste-like substance that adheres to ulcer craters and erosions, protecting them from acid and pepsin - It does **not affect acid secretion** or the H+/K+ ATPase enzyme *Famotidine* - **Famotidine** is another **H2 receptor antagonist**, similar to ranitidine, that works by reversibly blocking histamine H2 receptors on parietal cells [2] - Like ranitidine, it does **not directly inhibit the H+/K+ ATPase** enzyme

Q: A medical student presented to the ED with protracted vomiting. For this he was given an anti-emetic drug following which he developed abnormal posturing. Which of the following is the most likely drug to be given to the patient?

Metoclopramide. ***Metoclopramide*** - **Metoclopramide** is a **dopamine D2 receptor antagonist** that can cause **extrapyramidal symptoms (EPS)**, such as abnormal posturing (dystonia), due to its central action. - This adverse effect is more common with higher doses or in susceptible individuals, and the scenario directly describes it as a consequence of the antiemetic. *Ondansetron* - **Ondansetron** is a **5-HT3 receptor antagonist** primarily used for nausea and vomiting, particularly chemotherapy-induced. - It works **peripherally and centrally** but its side effect profile does not typically include extrapyramidal symptoms like abnormal posturing. *Domperidone* - **Domperidone** is also a **dopamine D2 receptor antagonist**, but it has **limited penetration across the blood-brain barrier**. - Due to its predominantly peripheral action, it causes **fewer central nervous system side effects**, including extrapyramidal symptoms, compared to metoclopramide. *Dexamethasone* - **Dexamethasone** is a **corticosteroid** with antiemetic properties, often used in conjunction with other antiemetics, especially in chemotherapy. - Its mechanism is not related to dopamine receptors, and it **does not typically cause extrapyramidal symptoms or abnormal posturing**.

Q: Which of the following is the primary neurotransmitter involved in nausea and vomiting associated with chemotherapy?

Serotonin. ***Serotonin*** - **Serotonin (5-HT)**, particularly acting on **5-HT3 receptors**, is a major neurotransmitter mediating chemotherapy-induced nausea and vomiting (CINV). - Chemotherapeutic agents can damage **enterochromaffin cells** in the gastrointestinal tract, leading to the release of serotonin, which then stimulates vagal afferents and the **chemoreceptor trigger zone (CTZ)**. *Dopamine* - **Dopamine (D2 receptors)** plays a role in nausea and vomiting, particularly in the **chemoreceptor trigger zone (CTZ)**. - While dopamine antagonists can be used as antiemetics, **serotonin** is considered the primary neurotransmitter in CINV due to the direct impact of chemotherapy on serotonin release. *Acetylcholine* - **Acetylcholine** is involved in motion sickness and is targeted by **anticholinergic antiemetics (e.g., scopolamine)**. - Its primary role in CINV is less significant compared to serotonin, which has a more direct link to the mechanisms of chemotherapy. *GABA* - **GABA (gamma-aminobutyric acid)** is the main inhibitory neurotransmitter in the brain and can reduce anxiety and modulate vomiting. - While **benzodiazepines**, which enhance GABAergic activity, are used as adjuncts in CINV to reduce **anticipatory nausea** and anxiety, GABA itself is not the primary mediator of the emetic response to chemotherapy.

Q: A patient with gastroesophageal reflux disease (GERD) is prescribed a proton pump inhibitor to reduce stomach acid production. Which enzyme is targeted by this drug?

H+/K+ ATPase. ***H+/K+ ATPase*** - Proton pump inhibitors (PPIs) directly target the **H+/K+ ATPase** (proton pump) in the parietal cells of the stomach [1], [2]. - This enzyme is responsible for the final common pathway of **acid secretion**, actively pumping hydrogen ions into the gastric lumen in exchange for potassium ions [1]. *Pepsin* - Pepsin is a **proteolytic enzyme** that becomes active in acidic environments but is not directly targeted by PPIs [1]. - While PPIs reduce the acidity required for optimal pepsin activity, they do not inhibit the enzyme itself. *Gastric lipase* - Gastric lipase is an enzyme involved in the digestion of **dietary fats** in the stomach. - It works optimally in an acidic environment, but PPIs do not directly inhibit its action. *Carbonic anhydrase* - **Carbonic anhydrase** is an enzyme that catalyzes the formation of carbonic acid, which then dissociates to provide hydrogen ions for the H+/K+ ATPase. - While it's involved in acid production, it's not the direct target of PPIs; instead, it's targeted by **carbonic anhydrase inhibitors** (e.g., acetazolamide), primarily used as diuretics or to treat glaucoma.

Q: A patient presents with a severe gastrointestinal ulcer due to nonsteroidal anti-inflammatory drugs (NSAIDs). Which agent would help reduce acidity and promote healing?

Pantoprazole. ***Pantoprazole*** - As a **proton pump inhibitor (PPI)**, pantoprazole potently and irreversibly blocks the H+/K+-ATPase pump in gastric parietal cells, significantly reducing **acid secretion** and promoting ulcer healing. - PPIs are the most effective class of drugs for treating and preventing **NSAID-induced ulcers** due to their superior acid-suppressing capabilities. - **First-line therapy** for severe NSAID-induced ulcers with the best evidence for healing and prevention. *Aluminum hydroxide* - This is an **antacid** that neutralizes existing stomach acid, providing temporary relief but not significantly promoting long-term ulcer healing. - Its effects are short-lived, and it does not inhibit further acid production, making it less effective for severe ulcers. *Ranitidine* - Ranitidine is an **H2-receptor antagonist** that blocks histamine's action on parietal cells, thereby reducing acid secretion. - While historically used for acid reduction, it is generally less potent and slower-acting than PPIs like pantoprazole for severe ulcers and does not irreversibly inhibit the proton pump. - **Note:** Ranitidine has been withdrawn from most markets worldwide (2019-2020) due to NDMA contamination concerns. Other H2 blockers like **famotidine** are now preferred alternatives. *Sodium bicarbonate* - This is a rapidly acting **antacid** that neutralizes stomach acid by forming carbon dioxide, leading to temporary relief. - Its use can cause **metabolic alkalosis** and is not suitable for sustained acid reduction or the healing of severe ulcers due to its short duration of action and potential side effects.

Q: A patient with peptic ulcers is treated with a combination therapy that includes clarithromycin. What is the purpose of this antibiotic in the treatment regimen?

Eradicate Helicobacter pylori. ***Eradicate Helicobacter pylori***- **Clarithromycin** is a macrolide antibiotic and a key component of **H. pylori eradication regimens** [1].- It targets the bacteria directly to resolve the underlying infection causing peptic ulcers [1].- Successful eradication significantly reduces ulcer recurrence rates [1].- Used in combination with a **PPI** and another antibiotic (amoxicillin or metronidazole) [1, 2].*Reduce acid production*- Clarithromycin is an antibiotic with no effect on acid secretion- **Proton pump inhibitors (PPIs)** serve this role in combination therapy*Neutralize stomach acid*- This is the function of **antacids**, not antibiotics- Clarithromycin's action is antimicrobial, not acid-neutralizing*Promote mucosal healing*- While H. pylori eradication indirectly promotes healing [1], clarithromycin does not directly stimulate mucosal repair- **Acid suppression via PPIs** allows the gastric and duodenal mucosa to heal

Q: Which serotonin 5-HT3 receptor antagonist is the most effective for preventing chemotherapy-induced nausea and vomiting?

Ondansetron. ***Ondansetron*** - **Ondansetron** is a highly effective and commonly used **serotonin 5-HT3 receptor antagonist** specifically indicated for the prevention of **chemotherapy-induced nausea and vomiting (CINV)**. - It works by blocking serotonin receptors in the **chemoreceptor trigger zone (CTZ)** and on afferent vagal nerve fibers, thereby reducing the emetic response. *Domperidone* - **Domperidone** is a **dopamine receptor antagonist** that acts peripherally to increase gastrointestinal motility and is used for nausea, but it does not effectively target the 5-HT3 receptors involved in CINV. - It has a weaker antiemetic effect against CINV compared to 5-HT3 antagonists. *Metoclopramide* - **Metoclopramide** is a **dopamine receptor antagonist** with some 5-HT3 receptor antagonist properties at higher doses, but it is less selective and potent than ondansetron for 5-HT3 blockade. - It is often used for general nausea and vomiting but is not considered the most effective single agent for preventing severe CINV due to its broader receptor effects and potential for side effects like **extrapyramidal symptoms**. *Meclizine* - **Meclizine** is an **antihistamine** and **anticholinergic** agent primarily used for motion sickness and vertigo. - It does not act on serotonin 5-HT3 receptors and is therefore ineffective in preventing chemotherapy-induced nausea and vomiting.

Question 1

Colonoscopy performed on a 25 year old woman with eating disorder showed dark brown to black pigmentary deposit in the lining of the large intestine. Histopathology of biopsy revealed pigment laden macrophages within the lamina propria. On probing, the woman revealed use of laxatives for 9 months to lose weight. What could be the probable laxative agent that could have caused these findings?

Accepted Answer

Senna

Answer

Castor oil

Answer

Bisacodyl

Answer

Sorbitol

Question 2

Mechanism of action of teduglutide in short bowel syndrome:

Accepted Answer

GLP-2 analog that inhibits apoptosis

Answer

HT1A inhibitor

Answer

C-peptide analog

Answer

GLP-1 analog that inhibits apoptosis

Question 3

Which GI drug acts by irreversibly inhibiting H+/K+ ATPase?

Accepted Answer

Omeprazole

Answer

Ranitidine

Answer

Sucralfate

Answer

Famotidine

Question 4

A medical student presented to the ED with protracted vomiting. For this he was given an anti-emetic drug following which he developed abnormal posturing. Which of the following is the most likely drug to be given to the patient?

Accepted Answer

Metoclopramide

Answer

Ondansetron

Answer

Domperidone

Answer

Dexamethasone

Question 5

How do 5-HT3 receptor antagonists like ondansetron work to prevent nausea and vomiting?

Accepted Answer

Blocking serotonin receptors in the chemoreceptor trigger zone

Answer

Inhibiting dopamine release

Answer

Decreasing gastric acid secretion

Answer

Reducing gastrointestinal motility

Question 6

Which of the following is the primary neurotransmitter involved in nausea and vomiting associated with chemotherapy?

Accepted Answer

Serotonin

Answer

Dopamine

Answer

Acetylcholine

Answer

GABA

Question 7

A patient with gastroesophageal reflux disease (GERD) is prescribed a proton pump inhibitor to reduce stomach acid production. Which enzyme is targeted by this drug?

Accepted Answer

H+/K+ ATPase

Answer

Pepsin

Answer

Gastric lipase

Answer

Carbonic anhydrase

Question 8

A patient presents with a severe gastrointestinal ulcer due to nonsteroidal anti-inflammatory drugs (NSAIDs). Which agent would help reduce acidity and promote healing?

Accepted Answer

Pantoprazole

Answer

Aluminum hydroxide

Answer

Ranitidine

Answer

Sodium bicarbonate

Question 9

A patient with peptic ulcers is treated with a combination therapy that includes clarithromycin. What is the purpose of this antibiotic in the treatment regimen?

Accepted Answer

Eradicate Helicobacter pylori

Answer

Reduce acid production

Answer

Neutralize stomach acid

Answer

Promote mucosal healing

Question 10

Which serotonin 5-HT3 receptor antagonist is the most effective for preventing chemotherapy-induced nausea and vomiting?

Accepted Answer

Ondansetron

Answer

Domperidone

Answer

Metoclopramide

Answer

Meclizine

Drugs for Gastrointestinal Diseases — MCQs

Drugs for Gastrointestinal Diseases — MCQs

On this page

Practice by Chapter

Want unlimited practice?